Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AP Pharma makes new appointment

This article was originally published in Scrip

Executive Summary

The US speciality pharmaceutical company AP Pharma has named John Whelan vice-president of finance and chief financial officer. He succeeds Gregory Turnbull, who was serving as interim chief financial officer and will remain a company director and a member of the board's executive committee. Mr Whelan was previously chief operating officer and chief financial officer at Raven biotechnologies.

You may also be interested in...



Sandoz Hits Back At Biosimilar Misinformation

Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.

Spanish Consumer Health And Cosmetics Firms Eying Up China’s Online Self-Care Market

A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall. 

NeuClone Makes Progress On Ustekinumab

Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel